Patent Application
20230405076
The present invention relates to a composition comprising Akkermansia muciniphila and a green tea extract. In particular, the present invention relates to a composition comprising Akkermansia muciniphila and a green tea extract, wherein Akkermansia muciniphila is pasteurized. The compositions of the present invention are useful in the prevention or treatment of a metabolic disorder selected from the group comprising obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, diabetes mellitus, glucose intolerance, abnormal lipid metabolism, hyperglycemia, dyslipidemia, barrier function diseases including inflammatory bowel disease, Crohn's disease and ulcerative colitis, irritable bowel syndrome, gut contractility disorder, hypercholesterolemia, and atherogenic dyslipidemia and in particular obesity. Moreover, the compositions of the invention are useful in promoting weight loss, reducing visceral fat or improving the gut barrier function.
Obesity and overweight are a worldwide trend, with an estimated number of obese adults of about 600 million. The prevalence of obesity-related disorders, such as, for example, diabetes, hypertension, cardiac pathologies and liver diseases. Due to these highly disabling pathologies, obesity is currently considered in Western countries as one of the most important public health problems.
Obesity is associated with metabolic dysfunctions with an impact on glucose homeostasis and lipid metabolism for example. Another comorbidity is low grade inflammatory state associated with higher blood lipopolysaccharides (LPS) levels also referred as metabolic endotoxemia.
A further comorbidity of obesity is impaired or reduced gut barrier function. Increased gut permeability leads to translocation of bacteria and/or microorganisms components into the bloodstream and organs such as the liver or the adipose tissue. Intestinal inflammation, LPS and bacterial translocation are also observed during inflammatory bowel diseases. Examples include Crohn's disease, colitis, ulcerative colitis, intestinal or colic pain and other intestinal inflammatory diseases. Interestingly, both inflammatory bowel diseases and obesity-related diseases are associated with changes in the gut microbiota composition.
The human gut is colonized by a diverse, complex and dynamic community of microbes representing over 1000 different species, which continuously interact with the host. The gut microbiota depends on host characteristics such as age, gender, genetic background. Other factors include environmental conditions such as stress, drugs, gastrointestinal surgery, infectious and toxic agents and day-to-day dietary changes.
Gut microbiota impact the development of obesity and related disorders, overweight and intestinal inflammation, or intestinal pain, dysbiosis of the microbiota can further disrupt the crosstalk between organs and the integrity of the intestinal barrier leading to symptoms.
Green tea has been described for the treatment of obesity or glycemia. For example, Kobayashi et al. (2000) (https://pubs.acs.org/doi/pdf/10.1021/jf0006832) discloses that green tea polyphenols inhibit glucose uptake. However, this document does not disclose a composition comprising Akkermansia muciniphila and green tea extract.
WO2013130773A2 to Kaplan discloses a method of altering relative abundance of microbiota in a subject comprising administering to the subject an effective dose of a composition consisting essentially of substantially purified Verrucomicrobia for the treatment of obesity and metabolic syndrome.
WO2014076246 to Université catholique de Louvain and Wageningen Universiteit describes the use of Akkermansia muciniphila for treating obesity and related disorders. However, this document does not disclose a composition comprising Akkermansia muciniphila and green tea extract.
EP3347030 to Université catholique de Louvain and Wageningen Universiteit describes Akkermansia muciniphila for use in treating a metabolic disorder in a subject in need thereof, wherein Akkermansia muciniphila is pasteurized. This document does not describe the combination of Akkermansia muciniphila with a plant extract.
Ushiroade 2019 discloses an increase of the Akkermansia genus in the Verrucomicrobia in high fat diet mice following the administration of the green tea compound Epigallocatechin-3-gallate. The document is available at Ushiroda et al., Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in highfat diet fed mice; J. Clin. Biochem. Nutr.|July 2019|vol. 65|no. 1|34-46, doi: 10.3164/jcbn.18116. However, this document does not disclose a composition comprising Akkermansia muciniphila and Green tea extract.
Sheng 2018 describes an epigallocatechin-3-gallate (EGCG) promoted increase of Akkermansia muciniphila effectively reduces diet-increased obesity, visceral fat, and insulin resistance. This document does not describe a composition comprising pasteurized Akkermansia muciniphila and green tea extract. The document is available at: Sheng et al., Obesity treatment by epigallocatechin-3-gallate-regulated bile acid signaling and its enriched Akkermansia muciniphila, FASEB J. 2018 December; 32(12): 6371-6384, doi: 10.1096/fj.201800370R.
US2018318323A1 to Plexus Worldwide discloses a gut microbiome modulating composition comprising green tea to stimulate the growth of Akkermansia. However, this document does not disclose a composition comprising Akkermansia muciniphila and green tea extract.
CN108541953 to Zhang Quingyu discloses tea polyphenols as a prebiotic to enhance the proliferation of Akkermansia muciniphila in cecum and ileum. This document does not disclose a composition comprising Akkermansia muciniphila and green tea extract.
However, there is still an urgent need to provide improved compositions for treating metabolic disorder, in particular obesity and promoting weight loss.
The present inventors have surprisingly found that the association of Akkermansia muciniphila and a green tea extract provides superior weight loss results as compared to other plant extracts and thus is synergistic. This is particularly the case, when Akkermansia muciniphila is pasteurized.
Accordingly, a first aspect of the invention is a composition comprising Akkermansia muciniphila and a green tea extract.
In a further aspect of the invention, Akkermansia muciniphila is pasteurized.
A further aspect of the invention is a composition for use in the prevention or treatment of a metabolic disorder selected from the group comprising obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, diabetes mellitus, glucose intolerance, abnormal lipid metabolism, hyperglycemia, dyslipidemia, barrier function diseases including inflammatory bowel disease, Crohn's disease and ulcerative colitis, irritable bowel syndrome, gut contractility disorder, hypercholesterolemia, gut barrier function disorder and atherogenic dyslipidemia.
In a further aspect of the invention, the metabolic disorder is obesity or gut barrier function disorder.
In a further aspect of the invention, the composition reduces the development of fat mass, in particular of visceral adipose tissue as compared to a non-treated subject.
In a further aspect of the invention, the composition further comprises one or more ingredients chosen from group consisting of probiotic, bacteria, yeast, microorganisms, prebiotic or a combination thereof.
In a further aspect of the invention, the composition further comprises a mineral or a vitamin or a combination thereof.
In a further aspect of the invention, the composition further comprises a pharmaceutically acceptable carrier or a food grade carrier.
In a further aspect the invention, the composition is orally administered.
In a further aspect of the invention, the pasteurized Akkermansia muciniphila is administered in an amount from 1.104 to 1.1012 cells per day, more preferably from 1.105 cells to 1.1011 cells per day, and even more preferably from 1.106 to 1.1010 cells per day, preferably as expressed in TFU by flow cytometry.
In a further aspect of the invention, the green tea extract is administered in an amount of 30 mg to 600 mg per day. In another embodiment, the green tea extract is administered in an amount up to 1000 mg or even 2000 mg per day.
In a further aspect of the invention, the green tea has 10 or even less 5% w % or more, preferably 50 w % or more of Epigallocatechin gallate (EGCG).
In a further aspect of the invention, the green tea extract is administered in an amount that delivers 100 mg to 600 mg per day EGCG. In a further aspect of the invention, the green tea extract is administered in an amount that delivers 200 mg to 300 mg per day of EGCG.
In a further aspect of the invention, the composition is a cosmetic composition, a nutritional composition, a food product, a dietary complement, a medical food or a medicament.
In a further aspect of the invention, the composition further comprises a second plant extract.
In a further aspect of the invention, the second plant extract is chosen from the group consisting of Aronia melanocarpa, Emblica officinalis, Olea Europa, Citrus bergamia, Vaccinium macrocarpon, Myrciaria dubia, red Panax ginseng, Vaccinium oxycoccos, Vaccinium macrocarpon.
A further aspect of the invention is a method of production of the composition of the invention comprising the steps of
A further aspect of the invention is a composition according to any of the preceding claims for promoting weight loss or the gut barrier function in a subject in need thereof.
A further aspect of the invention is a method of treating or preventing a metabolic disorder in a subject in need thereof, wherein the method comprises administering to the subject an effective amount in particular without treatment-limiting side-effects, of a composition comprising Akkermansia muciniphila and green tea extract. In a preferred embodiment, Akkermansia muciniphila is pasteurized.
“Treatment” means reducing or alleviating at least one adverse effect or symptom of a disease, disorder or condition. This term thus refers to both therapeutic treatment and prophylactic or preventative measures.
“Prevention” means preventing in the sense of keeping from happening or reducing the risk of a disease or condition.
“Effective amount” or “therapeutically effective amount” refers to level or amount of agent that is aimed at, without causing significant negative or adverse side effects to the target, delaying or preventing the onset of a metabolic disorder, slowing down or stopping the progression, aggravation, or deterioration of one or more symptoms of the metabolic disorder; bringing about ameliorations of the symptoms of the metabolic disorder; reducing the severity or incidence of the metabolic disorder; curing the metabolic disorder; or restoring the normal amount and/or proportion of Akkermansia muciniphila in the gut of the subject to be treated.
“Akkermansia muciniphila” refers to the mucin-degrading bacteria identified by Derrien (Derrien et al., 2004. Int. J. Syst. Evol. Microbiol. 54:1469-1476). Cells are oval-shaped, non-motile and stain Gram-negative. Akkermansia muciniphila may also be referred as Akkermansia spp. or Akkermansia-like bacteria. It belongs to the Verrucomicrobia phylum. It is generally accepted that strains with a nucleotide similarity as experimentally determined by DNA-DNA hybridization of about 70% can be considered as the same species—this corresponds to an average nucleotide identity (ANI) of approximately 95%.
In one embodiment, Akkermansia muciniphila also comprises fragments of Akkermansia muciniphila.
“Pasteurized Akkermansia muciniphila” refers to Akkermansia muciniphila submitted to a heating treatment. In one embodiment, pasteurized Akkermansia muciniphila refers to Akkermansia muciniphila which was heated at a temperature from 50° C. to 100° C. for at least 10 minutes.
“TFU” or “Total Fluorescent Units” means the number of cells as determined by their fluorescence radiance after staining. In a preferred embodiment, the TFU is measured flow cytometry. For example, in a first step, aliquots of biomass batches are rehydrated in PBS and stained with Syto 9 and propidium iodide according manufacturer protocol (LIVE/DEAD® BacLight™ Bacterial Viability Kit, Thermofisher). The TFU may then be obtained by analyzing the stained samples on Attune NxT flow cytometer. In general, TFU are expressed as total fluorescent unit per gram or per ml, preferably per gram.
“Green tea extract” means any extract of plant leaves or buds of Camellia sinensis. Green tea extract is in general rich in polyphenols, in particular epigallocatechin gallate (EGCG), epicatechin gallate, epicatechins and flavanols. Green tea extract may be obtained by alcoholic extraction or water extraction, concentrated or not and processed into a liquid or powder.
“Probiotics” refers to live microorganisms which, when administered in an effective amount, provide a beneficial effect on the health or well-being of a subject. In one embodiment, these health benefits are associated with improving the balance of human or animal microbiota in the gastro-intestinal tract, or restoring normal microbiota.
“Prebiotic” refers to a substance, such as, for example, a substance which may not be digested by humans, but which modulates composition and/or activity of the gut microbiota through its metabolization by microorganisms in the gut, thus conferring a beneficial physiological effect on the host.
“Subject” refers to an animal, preferably a mammal, more preferably a human or an animal.
“Overweight” refers to a subject situation wherein said subject has a Body Mass Index (BMI) of 25 or more. As used herein, BMI is defined as the individual's body mass (in kg) divided by the square of his/her height (in meter).
“Obesity” refers to a subject situation wherein said subject has a BMI superior or equal to 30.
“Fragment” may refer to cellular components, metabolites, secreted molecules, vesicles and compounds resulting from the metabolism of Akkermansia muciniphila and the like. Fragments may be obtained, for example, by recovering the supernatant of a culture of Akkermansia muciniphila or by extracting cell components or cell fractions, metabolites or secreted compounds from a culture of Akkermansia muciniphila.
The applicant herein shows that the beneficial effects on metabolism observed after administration of a composition comprising Akkermansia muciniphila and a green tea extract, as showed in the examples for Akkermansia muciniphila.
Therefore, this invention relates to a composition comprising Akkermansia muciniphila and a green tea extract for treating, or for use in treating, metabolic disorders in a subject in need thereof.
As used herein, a metabolic disorder is a disorder related to an altered metabolic homeostasis, such as, for example, an altered glucose or lipid homeostasis.
In one embodiment of the invention, said metabolic disorder is obesity.
Examples of other metabolic disorders include, but are not limited to, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus including Type 1 Diabetes or Type 2 Diabetes, glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, pre-eclampsia, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, liver diseases such as, for example, fibrosis associated with obesity, or abnormal liver functions, including changes in bile production, inflammatory, immune and barrier function diseases such as, for example, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and irritable bowel syndrome, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer.
In one embodiment, hypercholesterolemia corresponds to a plasma cholesterol concentration superior or equal to 2 g/L or 5 mmol/L. In another embodiment, hypercholesterolemia corresponds to a ratio plasma concentration of total cholesterol:plasma concentration of HDL (high density lipoprotein cholesterol) superior or equal to 4.5:1, preferably 5:1.
In to one embodiment, pasteurized Akkermansia muciniphila of the invention are non-viable cells. As used herein, “non-viable cells” means cells that are not able to proliferate. Examples to visualize or counts cells of Akkermansia muciniphila have been provided by Derrien et al. (2008. Appl. Environ. Microbiol. 74:1646-8), Derrien et al. (2011. Frontiers Microbiol. 2:166-175) or Reunanen et al. (2015. Appl. Environ. Microbiol. 81(11):3655-62).
The composition of the invention may also comprise a pharmaceutically acceptable excipient or a food grade carrier, for example solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like. For human administration, preparations should meet general safety and purity standards as required by FDA Office of Biologics standards.
The present invention also relates to a medicament, medical food, food or dietary compliment comprising an effective amount of Akkermansia muciniphila or a fragment thereof and green tea extract.
The present invention also relates to a method for treating or preventing a metabolic disorder in a subject in need thereof, wherein said method comprises administering an effective amount of Akkermansia muciniphila or a fragment thereof and green tea extract to the subject in need thereof.
Another object of the invention is a method for restoring a normal proportion of Akkermansia muciniphila, fragments or other active compounds of Akkermansia muciniphila in the gut of a subject in need thereof, wherein said method comprises administering an effective amount of Akkermansia muciniphila or a fragment thereof and green tea extract to the subject.
In one embodiment of the invention, the composition of the invention is administered at least once a week, preferably at least twice a week, more preferably at least three times a week, and even more preferably at least four times a week. In another embodiment, the composition of the invention is administered at least once a day, and preferably at least twice a day.
In one embodiment, the composition of the invention is administered during 1 week, preferably during 2, 3, 4, 5, 6, 7 or 8 weeks or more or even permanently.
In one embodiment, the composition of the invention is administered for a period that lasts until the desired outcome is achieved, for example weight loss, the metabolic disorder treatment, or the decrease of cholesterol plasma level.
In one embodiment of the invention, the daily dosage of Akkermansia muciniphila administered is from 1.102 to about 1.1015 TFU/day, preferably from about 1.104 to about 1.1012 TFU/day, more preferably from about 1.105 to about 1.1011 TFU/day and even more preferably from about 1.106 to about 1.1010 TFU/day.
In another embodiment of the invention, the daily dosage of pasteurized Akkermansia muciniphila is from 1.106 to about 1.1012 cells/day, preferably from about 1.108 to about 1.1010 cells/day, more preferably from about 1.109 to about 1.1010 cells/day.
The present invention also relates to the cosmetic use of pasteurized Akkermansia muciniphila or a fragment thereof for promoting weight loss in a subject.
Another object of the invention is thus a cosmetic composition comprising a cosmetically effective amount of pasteurized Akkermansia muciniphila or a fragment thereof and green tea extract, and the use thereof for promoting weight loss in a subject. As used herein, a “cosmetically effective amount” refers to the amount of a cosmetic composition necessary and sufficient for promoting a cosmetic effect, such as, for example, for inducing weight loss in a subject.
In one embodiment of the invention, the composition, the pharmaceutical composition, the cosmetic composition or the medicament further comprises additional probiotic strains or species, such as, for example, bacterial probiotic strains or species. In another embodiment, the further strains are pasteurized. These probiotics include bacteria, or fungal strains or species, preferably yeast strains or species. In one embodiment, said additional probiotic strains or species are selected from those naturally present in the gut of the subject, preferably in the human gut, more preferably in the gut of healthy human subjects.
Examples of bacterial probiotic strains or species that may be used in the present invention include, but are not limited to Lactobacillus, Lactococcus, Bifidobacterium, Veillonella, Desemzia, Christensenella, Allobaculum, Coprococcus, Collinsella, Citrobacter, Turicibacter, Sutterella, Subdoligranulum, Streptococcus, Sporobacter, Sporacetigenium, Ruminococcus, Roseburia, Proteus, Propionobacterium, Leuconostoc, Weissella, Pediococcus, Streptococcus, Prevotella, Parabacteroides, Papillibacter, Oscillospira, Melissococcus, Dorea, Dialister, Clostridium, Cedecea, Catenibacterium, Butyrivibrio, Buttiauxella, Bulleidia, Bilophila, Bacteroides, Anaerovorax, Anaerostipes, Anaerofilum, Enterobacteriaceae, Fermicutes, Atopobium, Alistipes, Acinetobacter, Slackie, Shigella, Shewanella, Serratia, Mahella, Lachnospira, Klebsiella, Idiomarina, Fusobacterium, Faecalibacterium, Eubacterium, Enterococcus, Enterobacter, Eggerthella, Dysosmobacter, or Anaerobacterium.
Preferred probiotic strains are Lactobacillus, Lactococcus, Bifidobacterium, Christensenella, Clostridium, Anaerostipes, Faecalibacterium, Eubacterium, Enterococcus, Enterobacter, Eggerthella, Dysosmobacter, or Anaerobacterium.
Examples of prokaryote strains or species that may be used in the present invention include, but are not limited to Archaea, Firmicutes, Verrucomicrobia, Christensenella, Bacteroidetes (such as, for example, Allistipes, Bacteroides ovatus, Bacteroides splachnicus, Bacteroides stercons, Parabacteroides, Prevotella ruminicola, Porphyromondaceae, and related genus), Proteobacteria, Betaproteobacteria (such as, for example, Aquabacterium and Burkholderia), Gammaproteobacteria (such as, for example, Xanthomonadaceae), Actinobacteria (such as, for example, Actinomycetaceae and Atopobium), Fusobacteria, Methanobacteria, Spirochaetes, Fibrobacteres, Deferribacteres, Deinococcus, Thermus, Cyanobacteria, Methanobrevibacteria, Peptostreptococcus, Ruminococcus, Coprococcus, Subdolingranulum, Dorea, Bulleidia, Anaerofustis, Gemella, Roseburia, Dialister, Anaerotruncus, Staphylococcus, Micrococcus, Propionobacteria, Enterobacteriaceae, Faecalibacterium, Bacteroides, Parabacteroides, Prevotella, Eubacterium, Bacilli (such as, for example, Lactobacillus salivarius and related species, Aerococcus, Granulicatella, Streptococcus bovis and related genus and Streptococcus intermedius and related genus), Clostridium (such as, for example, Anaerobutyricum hallii, Eubacterium limosum, Anaerobutyricum soehngenii and related genus) and Butyrivibrio.
Examples of fungal probiotic strains or species, preferably yeast probiotic strains or species that may be used in the present invention include, but are not limited Ascomycetes, Zygomycetes and Deuteromycetes, preferably from the groups Aspergillus, Torulopsis, Zygosaccharomyces, Hansenula, Candida, Saccharomyces, Clavispora, Bretanomyces, Pichia, Amylomyces, Zygosaccharomyces, Endomycess, Hyphopichia, Zygosaccharomyces, Kluyveromyces, Mucor, Rhizopus, Yarrowia, Endomyces, Debaryomyces, and/or Penicillium.
In one embodiment of the invention, the only one microbial strain or species, preferably bacterial strain or species, comprised in the composition, pharmaceutical composition, cosmetic composition or medicament is Akkermansia muciniphila.
In one embodiment of the invention, the composition, pharmaceutical composition, cosmetic composition or medicament consists of pasteurized Akkermansia muciniphila.
In one embodiment of the invention, the composition, the pharmaceutical composition, the cosmetic composition or the medicament further comprises a prebiotic.
Examples of prebiotics that may be used in the present invention include, but are not limited to, inulin and inulin-type fructans, oligofructose, beta-glucans, xylose, arabinose, arabinoxylan, ribose, galactose, rhamnose, cellobiose, fructose, lactose, salicin, sucrose, glucose, esculin, tween 80, trehalose, maltose, mannose, mellibiose, mucus or mucins, raffinose, fructooligosaccharides, galacto-oligosaccharides, amino acids, alcohols, fermentable carbohydrates and any combinations thereof.
Other non-limiting examples of prebiotics include water-soluble cellulose derivatives, water-insoluble cellulose derivatives, unprocessed oatmeal, metamucil, bran, and any combinations thereof.
Examples of water-soluble cellulose derivatives include, but are not limited to, methylcellulose, methyl ethyl cellulose, hydroxyethyl cellulose, ethyl hydroxyethyl cellulose, cationic hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, and carboxymethyl cellulose.
The composition of the invention may be administered by oral administration, rectal administration, administration via esophagogastroduodenoscopy, administration via colonoscopy, administration using a nasogastric or orogastric tube.
The composition may be administered orally as tablets, pills, capsules, soft gelatin capsules, sugarcoated pills, or dispersing tablets, effervescent tablets or other solids.
The composition may be administered orally as a liquid, a drinkable solution or a liposome.
In one embodiment, the composition of the invention further comprises excipients, diluent and/or carriers selected with regard to the intended route of administration. Examples of excipients, diluent and/or carriers include, but are not limited to, water, phosphate buffer saline, anaerobic phosphate buffer saline, sodium bicarbonate, juice, milk, yogurt, infant formula, dairy product, coloring agents, such as, for example, titane dioxide (E171), iron dioxide (E172) and brilliant black BN (E151); flavoring agents; thickeners, such as, for example, glycerol monostearate; sweeteners; coating agents, such as, for example, refined colza oil, soya oil, peanut oil, soya lecithin or fish gelatin; diluting agents, such as, for example, lactose, monohydrated lactose or starch; binding agents, such as, for example, povidone, pregelatinized starch, gums, saccharose, polyethylene glycol (PEG) 4000 or PEG 6000; disintegrating agents, such as, for example, microcrystalline cellulose or sodium carboxymethyl starch, such as, for example, sodium carboxymethyl starch type A; lubricant agents, such as, for example, magnesium stearate; flow agent, such as, for example, colloidal anhydrous silica, etc.
In one embodiment of the invention, the composition of the invention is a pharmaceutical composition.
In another embodiment, the composition of the invention is a food additive, drink additive, dietary supplement, nutritional product, medical food or nutraceutical composition.
Obesity and related disorders are associated with an increased gut permeability and with impaired mucus production, epithelium barrier, immune system and/or antibacterial compounds production by the subject.
Accordingly, the composition of the present invention may be used for decreasing gut permeability, for restoring impaired mucus production, for restoring epithelium barrier, for restoring immune system, or for restoring the production of antibacterial compounds or a combination thereof.
Moreover, the composition of the invention may be useful in controlling gut barrier function. Accordingly, another aspect is a method for controlling gut barrier function comprising administering an effective or cosmetically effective amount of the composition of the invention to a subject in need thereof.
In one embodiment, the composition of the invention regulates mucus layer thickness which may be decreased in obesity or other metabolic disorders. In another embodiment, the administration of the composition of the invention induces the production of colon antimicrobial peptides, such as, for example, RegIIIgamma. In another embodiment, the administration of composition of the invention induces the production of compounds of the endocannabinoids family, such as, for example, acylglycerols selected from the group comprising 2-oleoylglycerol, 2-palmitoylglycerol and 2-arachidonoylglycerol. In another embodiment, the administration of the composition of the invention regulates mucus turnover.
In one embodiment, the administration of the composition of the invention to a subject increases satiety in said subject. Consequently, according to this embodiment, the method of the invention increases satiety or decreases food intake in a subject, thereby inducing durable weight loss in the subject, and thereby treating metabolic disorders in said subject, such as, for example, obesity related metabolic disorders.
Nine-week-old male C57BL/6J mice (Charles River Laboratory, l'Arbresle, France) were allowed to at least 5 days of acclimatization period after the arrival. The animals were housed in ventilated and enriched cages (48×37.5×21 cm3) throughout the experimental phase. Animals' cages litters were changed once weekly. Mice were housed in groups of 5 animals on a normal light cycle (at 07:00 pm lights off), 22±2° C. and 50±10% relative humidity. Housing parameters were daily recorded. During the acclimation phase, standard diet (RM1 (E) 801492, SDS) and tap water were provided ad libitum. During the experimental phase (12 weeks), High fat diet 45 kcal % (Research Diet #12451) (HFD group) and tap water were provided ad libitum. Mice were treated daily with an oral gavage of 180 μL of vehicle, or 180 μL A. muciniphila solution alone or 180 μL of A. muciniphila solution±each plant extract (Bergamote: 125 mg/kg; Ginseng: 50 mg/kg or Green tea: 300 mg/kg) for the 12 weeks of HFD treatment.
The body weight, the food and water intake were assessed weekly.
Proximal colon was homogenized individually and total RNA from tissues were prepared using TRIReagent (Sigma Aldrich) and RNeasy 96 QiAcube HT kit (Qiagen). Quantification analysis of total RNA was performed by analyzing 1 μl of each sample in Nanodrop (Ozyme). cDNA was prepared by reverse transcription of 1 μg total RNA using a RT iScript kit (Biorad). Real-time PCR was performed with the Via7 real-time PCR system and software (Applied biotechnology) using SYBR Green Real-Time PCR Master Mixes (Biorad) for detection. RPL19 was chosen as the housekeeping gene. All samples were performed in duplicate, and data were analyzed according to the 2ΔΔCT method. The identity and purity of the amplified product were assessed by melting curve analysis at the end of amplification.
Surprising, of the plant extracts green tea was the one, that combined with pasteurized Akkermansia muciniphila showed superior results on weight, weight gain (
The association of pasteurized Akkermansia muciniphila and green tea extract also improved the barrier function with a more pronounced effect on ZO-1, intectin, occluding and Claudin-3 (see
Nine-week-old male C57BL/6J mice (Charles River Laboratory, l'Arbresle, France) were allowed to at least 5 days of acclimatization period after the arrival. The animals were housed in ventilated and enriched cages (48×37.5×21 cm3) throughout the experimental phase. Animals' cages litters were changed once weekly. Mice were housed in groups of 5 animals on a normal light cycle (at 07:00 pm lights off), 22±2° C. and 50±10% relative humidity. Housing parameters were daily recorded. During the acclimation phase, standard diet (RM1 (E) 801492, SDS) and tap water were provided ad libitum. During the experimental phase (12 weeks), High fat diet 45 kcal % (Research Diet #12451) (HFD groups) and tap water were provided ad libitum, control mice receiving normal chow diet (RM1 (E) 801492, SDS) (NCD group). Mice were treated daily with an oral gavage of 180 μL of vehicle, or 180 μL pasteurized A. muciniphila solution (2.108 TFU/day) alone or in combination with Green Tea extract (300 mg/kg) for the 12 weeks of HFD treatment.
At the beginning of the protocol, 13 mice per group have been ordered to compensate for a potential mortality linked to the force-feeding or fight. All the mice were used to do the statistical analyses except for the pAkk group and pAkk+Green Tea group where respectively the 3-09 and 5-03 mice died due to the force-feeding.
After one week of treatment, HFD+pAkk, HFD+Green Tea extract, and the HFD+pAkk+Green Tea showed a body weight gain lower than that of the HFD Vehicle group (
Over time, the association of pAkk+Green Tea is still more effective than pAkk or Green Tea alone on body weight or bodyweight gain with a significant effect starting week 2 until the end of the protocol for body weight gain (
| Number | Date | Country | Kind |
|---|---|---|---|
| 20205802 | Nov 2020 | BE | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/080505 | 11/3/2021 | WO |
